A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Status:
RECRUITING
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.